Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
Advanced Science · 2025-04 · 12 (14)
DOI: 10.1002/advs.202501542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.02.2025. Verfasst von Junhong Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China. Hauptthemen laut MEDLINE: Mitoxantrone, Immunotherapy, Zeolites, Immunogenic Cell Death. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Nature Science Foundation of China, Discipline Leader Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Chemo‐immunotherapy, combining systemic chemotherapeutic drugs and immune checkpoint blockers, is a promising paradigm in cancer treatment. However, challenges such as limited induction of immune responses and systemic immune toxicity have hindered its clinical applications. Here, a zeolite imidazolate framework‐8 (ZIF‐8) that encapsulates mitoxantrone (MIT), an immune cell death (ICD)‐inducing chemotherapeutic agent (MIT@ZIF‐8), is synthesized using a one‐pot aqueous‐phase process. ZIF‐8 serves as a dual‐functional nanomaterial for chemo‐immunotherapy: a carrier to enhance tumor uptake of MIT for improved chemotherapy efficacy, and a pyroptosis inducer to amplify MIT‐induced ICD for augmented anti‐tumor immune responses. As a result, in vivo administration of MIT@ZIF‐8 markedly inhibits tumor growth in both immunologically “hot” colon cancer and immunologically “cold” prostate cancer. Moreover, MIT@ZIF‐8 treatment increases the abundance of cytotoxic CD8 + T cells and reduces the amount of immunosuppressive regulatory T cells in tumors, thereby enhancing anti‐tumor immunity and sensitizing prostate cancer to anti‐CTLA‐4 immunotherapy. In summary, MIT@ZIF‐8 offers a highly translational approach for chemo‐immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
- Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing, 100190, P. R. China.
- School of Future Technology, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- Foundation for Applied Molecular Evolution, Alachua, Florida, 32615, US.
ORCID-Profile: Jiashu Sun
Förderung
- National Key R&D Program of China
- National Nature Science Foundation of China
- Discipline Leader Project of Shanghai Municipal Health Commission
- CAS Project for Young Scientists in Basic Research
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Lv, W., Han, Z., Li, Y., Deng, J., Huang, Y., Wan, S., Sun, J., & Dai, B. (2025). Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death. Advanced Science, 12(14). https://doi.org/10.1002/advs.202501542
Vancouver
Li J, Lv W, Han Z, Li Y, Deng J, Huang Y, et al. Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death. Advanced Science. 2025;12(14). doi:10.1002/advs.202501542
BibTeX
@article{Li2025,
author = {Li, Junhong and Lv, Wenxing and Han, Ziwei and Li, Yike and Deng, Jinqi and Huang, Yanjuan and Wan, Shuo and Sun, Jiashu and Dai, Bo},
title = {Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {14},
doi = {10.1002/advs.202501542}
}
EUVIMED